H-CYTE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was USD 0.45346 million compared to USD 1.29 million a year ago. Net loss was USD 8.81 million compared to USD 4.05 million a year ago. Basic loss per share from continuing operations was USD 34.07 compared to USD 30 a year ago.